Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India

Recruiting N/A Interventional Study
Cervical Cancer Human Papillomavirus (HPV) Infection Human Immunodeficiency Virus (HIV) Infection
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
25 – 50
Sex
Female
Study type
Interventional
Purpose
Prevention
Participants needed
348 (estimated)
Sponsor
University of California, Irvine · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Cervical cancer (CC) remains one of the most common malignancies among women in India, with nearly 100,000 women diagnosed annually and over 60,000 preventable deaths annually. With high-risk human papillomavirus (HR-HPV) as the causative agent for CC, one risk factor that places women at high risk for CC is human immunodeficiency virus (HIV), as impaired immune response against Human papillomavir…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. WLH, 25 - 50 years of age; based on HIV-based guidelines; 2. Receiving ART for \> 12 months to ensure medication stabilization, and ensure any impact on the cervical cancer outcomes will not be attributed solely to recent ART initiation, as validated by an ART card given to a…
Contacts

Veena Satyanarayana

91-80-26995180/5877

veena.a.s@gmail.com

CONTACT